Introduction: Freestyle Libre Flash glucose monitoring system is a new approach to self-monitoring of glucose. We investigated the effect on glycaemic control of applying this system in patients with type 1 diabetes in a real world clinical setting.

Materials and Methods: A total of 210 consecutive patients with type 1 diabetes were included in an observational study investigating the change in glycaemic control upon introducing Freestyle Libre Flash Glucose monitoring (FGM) system (Abbott Diabetes Care Ltd, Range Road Witney, Oxon OX29 OYL; UK). Hba1c was monitored prior to the application of FGM and every 3-4 months during a follow-up of between 3 and 15 months.

Results: HbA1C decreased significantly by 5 mmol/mol (IQR 10, P <0.0001) after 3 months as compared with baseline, where after HbA1c stabilized.

When subdividing patients according to baseline glycemic control (Hba1c <53 mmol/mol, 54-70 mmol/mol, >70 mmol/mol) at inclusion in the study, we found a significant decrease in Hba1c in two groups (54-70: 4 mmol/mol, P<0.0001, >70: 7 mmol/mol, P<0.0001) from baseline to 3 months.

Conclusion: In this observational study, we found a significant decrease in Hba1c- levels after the introduction of flash glucose monitoring in subjects with type 1 diabetes; this decrease was maintained throughout the 12-month study period.

G.H. Dørflinger: None. J.A. Østergaard: None. S. Fisker: Other Relationship; Self; Novo Nordisk A/S. S.T. Knudsen: Advisory Panel; Self; Novo Nordisk A/S, Merck & Co., Inc., Sanofi-Aventis, Eli Lilly and Company, Boehringer Ingelheim GmbH, AstraZeneca. Speaker's Bureau; Self; Merck & Co., Inc., Boehringer Ingelheim GmbH, AstraZeneca. T.K. Hansen: Advisory Panel; Self; Abbott, AstraZeneca, Novo Nordisk A/S. Research Support; Self; Novo Nordisk Foundation. Advisory Panel; Self; Merck Sharp & Dohme Corp..

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at